Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00081484 · ClinicalTrials.gov registry record · Phase 3
A Study of Intravenous or Subcutaneous Mircera for the Treatment of Anemia in Dialysis Patients
A Phase 3 study, sponsored by Hoffmann-La Roche.
- Completed
- Registry status
- Phase 3
- Development phase
- 336
- Enrollment target
NCT00081484: Completed Phase 3 study, sponsored by Hoffmann-La Roche.
NCT00081484 is a Phase 3 study that has completed, run by Hoffmann-La Roche. The registered enrollment target is 336 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (56% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00081484, a Phase 3 study, has completed, sponsored by Hoffmann-La Roche.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 336 participants
- Enrollment target
Study Summary
This study will assess the efficacy and safety of intravenous (iv) or subcutaneous (sc) Mircera, administered with pre-filled syringes, as maintenance treatment for renal anemia in chronic kidney disease patients on dialysis who were previously receiving iv or sc epoetin. The anticipated time on study treatment is 3-12 months and the target sample size is 100-500 individuals.
Interventions
- DRUG methoxy polyethylene glycol-epoetin beta [Mircera]
- DRUG epoetin alfa or beta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 336 participants |
| Start Date | 2004-06 |
| Est. Completion | 2006-03 |
| Phase | Phase 3 |
What the finished NCT00081484 record still lists
NCT00081484 is an interventional study that assigns participants to a tested intervention. The registered 336 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (56% lower).
The record links to 0 conditions, and to 2 interventions - of which methoxy polyethylene glycol-epoetin beta [Mircera] is the first listed.
NCT00081484 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00081484 about?
NCT00081484 is a clinical study titled "A Study of Intravenous or Subcutaneous Mircera for the Treatment of Anemia in Dialysis Patients". This study will assess the efficacy and safety of intravenous (iv) or subcutaneous (sc) Mircera, administered with pre-filled syringes, as maintenance treatment for renal anemia in chronic kidney disease patients on dialysis who were previously receiving iv or sc epoetin. The anticipated time on stu...
What is the current status of trial NCT00081484?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 336 participants. The study started on 2004-06. Estimated completion is 2006-03.
What interventions are being tested in trial NCT00081484?
The interventions under investigation include: methoxy polyethylene glycol-epoetin beta [Mircera] (DRUG), epoetin alfa or beta (DRUG).
Who is sponsoring clinical trial NCT00081484?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00081484's enrollment target sits among peer trials
336 1060th of 2000 higher than 940 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03947385 · 336 participants · Phase 1
Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions
- NCT03977207 · 336 participants · NA
A Randomized Controlled Trial of Thyroid Hormone Supplementation in Hemodialysis Patients
- NCT04665206 · 336 participants · Phase 1
Study to Evaluate VT3989 in Patients With Metastatic Solid Tumors
- NCT05124457 · 336 participants · Phase 2
DETERMINE: Detemir vs NPH
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia